Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Cancer Res Treat · 2019 · PMC6473268 · PMID 29898592

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep=0.06so close (0.05 < p ≤ 0.1)

Compared with gefitinib and erlotinib, afatinib treatment yielded a longer PFS for patients with uncommon EGFR mutations, although this difference did not reach statistical significance, possibly due to the small sample size (p=0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.